Sullivan D - Search Results

1

Phase II trial of karenitecin in patients with malignant melanoma: clinical and translational study.

Daud A, Valkov N, Centeno B, Derderian J, Sullivan P, Munster P, Urbas P, Deconti RC, Berghorn E, Liu Z, Hausheer F, Sullivan D. Daud A, et al. Among authors: sullivan p, sullivan d. Clin Cancer Res. 2005 Apr 15;11(8):3009-16. doi: 10.1158/1078-0432.CCR-04-1722. Clin Cancer Res. 2005. PMID: 15837755 Clinical Trial.

2

Quantitative immunofluorescence and immunoelectron microscopy of the topoisomerase II alpha associated with nuclear matrices from wild-type and drug-resistant chinese hamster ovary cell lines.

Valkov NI, Gump JL, Sullivan DM. Valkov NI, et al. Among authors: sullivan dm. J Cell Biochem. 1997 Oct 1;67(1):112-30. doi: 10.1002/(sici)1097-4644(19971001)67:1<112::aid-jcb12>3.0.co;2-j. J Cell Biochem. 1997. PMID: 9328845

3

Drug resistance to DNA topoisomerase I and II inhibitors in human leukemia, lymphoma, and multiple myeloma.

Valkov NI, Sullivan DM. Valkov NI, et al. Among authors: sullivan dm. Semin Hematol. 1997 Oct;34(4 Suppl 5):48-62. Semin Hematol. 1997. PMID: 9408961 Review.

4

Effects of wild-type p53 expression on the quantity and activity of topoisomerase IIalpha and beta in various human cancer cell lines.

Hochhauser D, Valkov NI, Gump JL, Wei I, O'Hare C, Hartley J, Fan J, Bertino JR, Banerjee D, Sullivan DM. Hochhauser D, et al. Among authors: sullivan dm. J Cell Biochem. 1999 Nov 1;75(2):245-57. doi: 10.1002/(sici)1097-4644(19991101)75:2<245::aid-jcb7>3.3.co;2-7. J Cell Biochem. 1999. PMID: 10502297

5

Cell density-dependent VP-16 sensitivity of leukaemic cells is accompanied by the translocation of topoisomerase IIalpha from the nucleus to the cytoplasm.

Valkov NI, Gump JL, Engel R, Sullivan DM. Valkov NI, et al. Among authors: sullivan dm. Br J Haematol. 2000 Feb;108(2):331-45. doi: 10.1046/j.1365-2141.2000.01832.x. Br J Haematol. 2000. PMID: 10691864 Free article.

6

Histone deacetylase interacts directly with DNA topoisomerase II.

Tsai SC, Valkov N, Yang WM, Gump J, Sullivan D, Seto E. Tsai SC, et al. Among authors: sullivan d. Nat Genet. 2000 Nov;26(3):349-53. doi: 10.1038/81671. Nat Genet. 2000. PMID: 11062478

7

Reduction in drug-induced DNA double-strand breaks associated with beta1 integrin-mediated adhesion correlates with drug resistance in U937 cells.

Hazlehurst LA, Valkov N, Wisner L, Storey JA, Boulware D, Sullivan DM, Dalton WS. Hazlehurst LA, et al. Among authors: sullivan dm. Blood. 2001 Sep 15;98(6):1897-903. doi: 10.1182/blood.v98.6.1897. Blood. 2001. PMID: 11535527 Free article.

8

Tumor p53 status and response to topoisomerase II inhibitors.

Valkov NI, Sullivan DM. Valkov NI, et al. Drug Resist Updat. 2003 Feb;6(1):27-39. doi: 10.1016/s1368-7646(02)00143-7. Drug Resist Updat. 2003. PMID: 12654285 Review.

9

The cytoplasmic trafficking of DNA topoisomerase IIalpha correlates with etoposide resistance in human myeloma cells.

Engel R, Valkov NI, Gump JL, Hazlehurst L, Dalton WS, Sullivan DM. Engel R, et al. Exp Cell Res. 2004 May 1;295(2):421-31. doi: 10.1016/j.yexcr.2004.01.012. Exp Cell Res. 2004. PMID: 15093741

10

Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid.

Marchion DC, Bicaku E, Daud AI, Richon V, Sullivan DM, Munster PN. Marchion DC, et al. J Cell Biochem. 2004 May 15;92(2):223-37. doi: 10.1002/jcb.20045. J Cell Biochem. 2004. PMID: 15108350

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,591 results

Search Page

Filters